Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 12/20 | 0.67 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28513485 | 1.00 | USP30 (0.67) | USP30RIPK1PARP1HDAC4HDAC6 | |
| SCHEMBL18124183 | 1.00 | USP30 (0.67) | USP30RIPK1PARP1HDAC4HDAC6 | |
| SCHEMBL29779090 | 0.88 | USP30 (0.70) | USP30RIPK1PARP1HDAC4HDAC6 | |
| SCHEMBL18124204 | 0.88 | USP30 (0.70) | USP30RIPK1PARP1HDAC4HDAC6 | |
| SCHEMBL23019685 | 0.88 | USP30 (0.70) | USP30RIPK1PARP1HDAC4HDAC6 | |
| SCHEMBL18115907 | 0.83 | CRBN (0.50) | USP30HRH3 | |
| SCHEMBL19990874 | 0.83 | CRBN (0.50) | USP30HRH3 | |
| SCHEMBL23970939 | 0.82 | USP30 (0.56) | USP30RIPK1PARP1HDAC4HDAC6 | |
| SCHEMBL23019804 | 0.82 | USP30 (0.63) | USP30RIPK1PARP1HDAC4HDAC6 | |
| SCHEMBL23019729 | 0.82 | USP30 (0.68) | USP30RIPK1PARP1HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| CN-112707893-B | 1-cyanopyrrolidine compounds as USP30 inhibitors | 特殊治疗有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20220251041-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-08-11 | — | — | US | disclosed |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251041-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | USP30 1/4885RIPK1 1397/4885PARP1 683/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | USP30 1/4885RIPK1 1769/4885PARP1 346/4885 |
| US-11390584-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | USP30 1/4885RIPK1 1354/4885PARP1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.